Drugmaker UCB pleads guilty to off-label marketing

The maker of epilepsy treatment Keppra agreed Thursday to pay more than $34 million for marketing the medication to treat migraine headaches in violation of U.S. drug laws.

The maker of epilepsy treatment Keppra agreed Thursday to pay more than $34 million for marketing the medication to treat migraine headaches in violation of U.S. drug laws.

The U.S. subsidiary of Belgian manufacturer UCB pleaded guilty in federal court in Washington to a misdemeanor in connection with the misbranding.

The government had approved Keppra to treat seizures in adults and children with epilepsy. A manufacturer may not market or promote a drug for any use not specified in its approved product label. But prosecutors said UCB claimed studies showed Keppra was safe and effective for treating migraines, without disclosing that UCB sponsored the studies or that the company's own clinical trial failed to demonstrate such effectiveness.

UCB, which has its U.S. headquarters in Smyrna, Ga., will pay a $7.55 million criminal fine, forfeit $1 million in assets and pay $25.7 million to resolve civil claims that it promoted off-label uses including migraine, pain, bipolar, mood disorders and anxiety.

The federal government will get $15.8 million of the civil settlement and nearly $10 million will go to state Medicaid programs. The settlement resolves two lawsuits brought by whistleblowers, who will together receive payments of more than $2.8 million from the federal share.

The plea is part of an ongoing Obama administration initiative against health care fraud, including the promotion of drugs for uses the Food and Drug Administration has not approved as safe and effective. The Justice Department said it has recovered more than $5.7 billion in Medicare and Medicaid fraud cases since January 2009.

"UCB put its pursuit of profits ahead of its obligations to patients," said Ronald C. Machen Jr., U.S. attorney for the District of Columbia. "Today's guilty plea and UCB's $34 million payout should remind drug companies that try to cleverly design off-label marketing schemes that we will not allow them to compromise patient safety."

In Other News

fake money

Keywords clouds text link http://alonhatro.com

 máy sấy   thịt bò mỹ  thành lập doanh nghiệp
Visunhomegương trang trí  nội thất  cửa kính cường lực   lắp camera Song Phát thiết kế nhà 

Our PBN System:  thiết kế nhà xưởng thiết kế nội thất thiết kế nhà tem chống giả  https://thegioiapple.net/ https://24hstore.vn/

aviatorsgame.com ban nhạcconfirmationbiased.com 
mariankihogo.com  ốp lưngGiường ngủ triệu gia  Ku bet ku casino

https://maysayhaitan.com/  https://dovevn.com/ buy fake money https://sgnexpress.vn/ máy sấy buồn sấy lạnh

mặt nạ  mặt nạ ngủ  Mặt nạ môi mặt nạ bùn mặt nạ kem mặt nạ bột mặt nạ tẩy tế bào chết  mặt nạ đất sét mặt nạ giấy mặt nạ dưỡng mặt nạ đắp mặt  mặt nạ trị mụn
mặt nạ tế bào gốc mặt nạ trị nám tem chống giả

https://galaxymedia.vn/  công ty tổ chức sự kiện tổ chức sự kiện
Ku bet ku casino
Sâm tươi hàn quốc trần thạch cao trần thạch cao đẹp

suất ăn công nghiệpcung cấp suất ăn công nghiệp


© 2020 US News. All Rights Reserved.